Effects of empagliflozin in patients at risk of heart failure: the empire prevent metabolic trial - Summary - MDSpire

Effects of empagliflozin in patients at risk of heart failure: the empire prevent metabolic trial

  • By

  • Camilla Fuchs Andersen

  • Julie Hempel Larsen

  • Massar Omar

  • Nina Nouhravesh

  • Caroline Michaela Kistorp

  • Christian Tuxen

  • Filip K Knop

  • Per Lav Madsen

  • Julie Lyng Forman

  • Filip Søskov Davidovski

  • Lars Køber

  • Morten Schou

  • Jacob Eifer Møller

  • Jesper Jensen

  • January 8, 2026

  • 0 min

Share

Objective:

To investigate the effect of empagliflozin on estimated extracellular volume (eECV) and ventricular epicardial adipose tissue (EAT) mass in non-diabetic patients with overweight or obesity at risk of heart failure (HF).

Key Findings:
  • Empagliflozin significantly reduced eECV compared to placebo (mean change: -0.154 L vs -0.029 L, Padj = 0.004).
  • Empagliflozin did not significantly affect EAT mass (mean change: -2.3 g vs -3.7 g, Padj = 1.00).
  • The treatment was well-tolerated with few side effects.
Interpretation:

Empagliflozin may offer a beneficial reduction in extracellular fluid volume in high-risk overweight patients, potentially aiding in heart failure prevention, although it does not reduce epicardial adipose tissue mass.

Limitations:
  • The study population was limited to non-diabetic patients, which may affect generalizability.
  • The follow-up duration was only 180 days, limiting long-term outcome assessments.
Conclusion:

Empagliflozin shows promise in reducing eECV in overweight patients at risk for HF, but further studies are needed to evaluate its long-term effects and impact on EAT mass.

Original Source(s)

Effects of empagliflozin in patients at risk of heart failure: the empire prevent metabolic trial

  • by Camilla Fuchs Andersen, Julie Hempel Larsen, Massar Omar, Nina Nouhravesh, Caroline Michaela Kistorp, Christian Tuxen, Filip K Knop, Per Lav Madsen, Julie Lyng Forman, Filip Søskov Davidovski, Lars Køber, Morten Schou, Jacob Eifer Møller, Jesper Jensen

  • January 8, 2026

Related Content

Outcomes following coronary artery bypass grafting with temporary left ventricular assist device support

Case Report: Persistent fifth aortic arch with coarctation and fourth aortic arch interruption causing infant heart failure – the prenatal and postnatal echocardiographic course

Role of psychological resilience and psychological distress in linking fear of disease progression to quality of life in chronic heart failure: a cross-sectional serial mediation analysis